Article Sidebar

Submitted
Apr 26, 2021
Published
Apr 26, 2021
Download
PDF
Statistic
Read Counter : 126 Download : 70

Main Article Content

Abstract

Therapeutic drug monitoring of Phenytoin is carried out to ensure effective and safe levels. Some of the factors complicating Phenytoin dosing include a narrow therapeutic window, high degree of protein binding, and non-linear pharmacokinetics. However, serum drug levels should only be taken when there is a clear indication to guide patient management. Scenarios where monitoring levels may be clinically useful include 1; establish an individual therapeutic concentration 2, aiding in diagnosis of clinical toxicity 3, assisting patient compliance and 4, guiding dosage adjustment in patients likely to have greater pharmacokinetic variability. The therapeutic range of Phenytoin is 10-20 microgram/ml. The study was carried out at a tertiary care where Neurology dept is well developed. This was a retrospective study a total number of samples of 2239 were included. Patients were taking only on monotherapy, Phenytoin. Samples were of trough levels and were taking the same dosage regimen. Patients were in the age range from 10 yrs. to 70 yrs. comprised 52.38% males and 46.62% females. 75% samples were in therapeutic range.

Keywords

Phenytoin Therapeutic drug monitoring Out patients department Enzyme Multiplied Immuno Technique Glucose 6 phosphodehydrogenase

Article Details

How to Cite
Loan Gh. Mohammad, Tanki Shafiqa Aslam, & Shabir Ahmad. (2021). Therapeutic drug monitoring of phenytoin needs vigilance: An individualized PD response is variable. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(4), 406-410. https://doi.org/10.61096/ijrpp.v4.iss4.2015.406-410
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Perucca E and Richens A. Antiepileptic drugs: Clinical aspects. In: Richens and Marks (eds), Therapeutic Drug Monitoring Edinburg. Churchill Living Stone, New York, 1981, PP. 320-344.
  2. [2]. Hanneka M de Boer, Marco Mula and Josemir W Sander, The global burden and Stigma of Epilepsy in India. Epllepsia Behav, 12(4):540-546(2008).
  3. [3]. Sirdharan R, Murthy B N. Prevelance and pattern of epilepsy in India. Epilepsia May, 40(5): 631-636,(1999).
  4. [4]. Charles R. Craig. Chapter 32 Antiepileptic drugs. In: Charles R. Craig, Robert E. Stizel (eds.), Modern Pharmacology with Clinical Applications. 6th edition Lippincort Williams and Wilkins, New York, 2004, pp. 374-383.
  5. [5]. Williams R: Garnett and Pharma D. Chapter 55. Epilepsy: Joseph T. Dipro Robert L. Talbert, R. Matzre, G wells (eds.), Pharmacotherapy A Pathophysilogical approach. 3rd 1207.
  6. [6]. Dr. Vinitsuri, Caring for the Quality- Of-Life in Epilepsy Patients. Epilink, August: 1-5, (2004)
  7. [7]. Iain L. O. Bxton and Leslier Benet. Chapter 2. Pharmacokinetics: The Dynamics of Absorption, Distribution, Metabolism and Elimination. In: Laurence. L Bruton, Ph. D, Bruce A. Chabner MD, Bjorn C Knollmann, MD(eds), Goodman and Gillman’s The Pharmacological Basis of Therapeutics 12th Ednn. MacGraw-Hill Medical Publishing Division, Newyork, 2011, pp. 18-39.
  8. [8]. Pippenger C. E. Principles of Therapeutic Drug Monitoring In: Steven Wong, (eds.) Therapeutic Drug Monitoring and Toxicology by Liquid Chromatography, Marcel Deccar INC, New York, 1985, pp. 11-37.
  9. [9]. Dr Sangeetha Sharma, Therapeutic Drug Monitoring clinical utility and what to look for and when to look for it. Epilepsia, 41 (supplement 8): 25-33 (2000).
  10. [10]. Osellerich M, 1984: Determination of total and free Phenytoin in serum by non-isotopic immunoassay and gas chromatography, Journal of Clinical Chemistry and Clinical Biochemistry 773-780.
  11. [11]. Gross A S. Best practice in therapeutic drug monitoring. Br. J Clin. Pharmacol 1998; 46:95-98.
  12. [12]. Brophy G M, Tesoro EP, Schrote GL, Garnett WR. Pharmacist impact on post-traumatic seizure prophylaxis in patients with head injury. Pharmacotherapy 2002; 22(2): 251-255.
  13. [13]. Perucca, E, Dulac O, Shorvon S, Tomson T, 2001. Hamessing The Clinical Potential of antiepileptic drug monitoring. Ther Drug Monit. 2(4), 331-344.
  14. [14]. Ninomiya K, Mamiya K, Matsuo S, Ieri I, Higuchi S, Tashiro N. (2000). Genetic Polymorphism of the CYP 450 suub family and excessive serum Phenytoin concentration with central nervous intoxication. Therapeutic Drug Monitoring. Vol 22, No 2 (April 2000) 230-232. Print 0163-4356.
  15. [15]. Aronson JK, Hardman M, Renylods DJM. ABC of monitoring drug therapy: Phenytoin. BMJ 1992, 325(6863): 1215-1218.
  16. [16]. Fankhauser MP. Bipolar. In Dipiro JT, Talbert RL, Yee GC, Matzke, Wells BG, Posey LM, eds New York, NY: Mc Graw-Hill, 2002:133-139.
  17. [17]. Carson SW. Lithium In: Ewans In: Ewans WE, Schentag JJ, Jusk Jusko WJ eds. Applied Pharmacokinetics Principles of Therapeutic Drug Monitoring. 3rd ed Vancour, WA. Applied Therapeutic, Inc; 1992:34-1-34-26.